This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Regulatory/Suppressor T Cells (D1)


Organizer(s) Ethan M. Shevach and Luciano Adorini
March 10—15, 2004
Banff Centre • Banff, Alberta Canada
Abstract Deadline: Nov 10, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 12, 2004

Sponsored in part by the Director's Sponsor Fund

Summary of Meeting:
Although the concept of suppression mediated by T lymphocytes was originally proposed more than 30 years ago, recent studies in animal models of autoimmunity have rekindled interest in the existence of a subset of lymphocytes that specifically suppress immune responses. One population of naturally-occurring or endogenous T suppressor cells can be identified by co-expression of the CD4 and CD25 antigens. These cells suppress the activation of CD4 and CD8 T cells in vitro by an unknown cell-contact dependent mechanism. In vivo, these cells suppress autoimmune disease by both cell contact-dependent and suppressor cytokine-dependent pathways. Although these cells were originally described in the mouse, a population with identical phenotypic and functional properties has been identified in man. A second group of suppressor cells can be induced in vivo by oral exposure to antigen, by culture of T cells with cytokines (IL-10), or by pharmacologic manipulation of dendritic cell functions. These antigen-induced suppressors primarily inhibit T cell activation in vitro and in vivo by secreting suppressor cytokines. Determination of the cellular target and the molecular basis of CD4+CD25+ mediated suppression is a major area of current research. The nature of the physiologic ligand recognized by these cells is also unknown as is the breadth of their T cell repertoire. Suppressor/regulatory T cells have primarily been shown to inhibit animal models of autoimmune disease. However, recent studies have extended their range of activities to inhibition of tumor immunity, graft rejection, allergic disease, graft versus host disease, and acute and chronic infectious diseases. One critical area of future study will involve the development of protocols to enhance regulatory T cell function in vivo by pharmacologic means as such an approach should prove useful in autoimmunity, allergic disease, and graft rejection. Similarly, a related area will involve inhibition of regulatory T cell function, either transiently or permanently, by pharmacologic manipulation or treatment of animals or man with monoclonal antibodies specific for effector molecules on these cells. Protocols are now being developed for the adoptive immunotherapy of both CD4+CD25+ T cells that have been expanded in vitro and for suppressor cells that have been induced in vitro. These cells will be administered to patients with GVHD, graft rejection, and organ-specific and systemic autoimmune disease. This meeting will review all of the above issues and focus on the manipulation of regulatory T cell function in animal models of human disease as well as in disease in man.

View Meeting Program

Scholarships/Awards

Scholarship / Award Information


Scholarship Deadline: (11:59 PM US Mountain Standard Time)
*All deadlines end at 11:59 PM US Mountain Standard Time
NOTE: Please use the button above to Apply for a Scholarship

Scholarships

Keystone Symposia is offering scholarships of up to 1,200 USD to Students and Postdoctoral fellows. These scholarships are to be used to help defray the expenses associated with conference attendance, including airfare (restrictions may apply based on funding source), ground transportation, lodging costs, and a portion of meeting registration. Receipts will be required to receive reimbursement.

Abstracts submitted for poster presentation will be used as the basis for awarding the scholarships. Scholarship recipients will be selected based on the quality of science of the abstract and the relevance of the abstract to the conference topic. Only one application per abstract is accepted. Only one award per lab will be allocated.


Eligibility


To be eligible for a scholarship, you must be:

A graduate student or postdoctoral fellow currently enrolled in an academic institute at the start of the meeting for which you are applying. Note: a graduate student is defined as a student who is studying for a higher degree at an academic institution. A postdoctoral fellow is defined as an individual with a Ph.D., M.D., or DVM degree who is engaged in a temporary period of mentored research and/or scholarly training for the purpose of acquiring the professional skills needed to pursue their desired career path, and is within 6 years of these degrees.


Review Criteria


Criteria for Abstract Review:

  1. Relevance to the meeting topic
  2. Significance of the scientific question and results
  3. Style
    • Organization (e.g. the abstract has a clear beginning, middle and end)
    • Grammar and spelling
  4. Clarity of scientific presentations
    • Clear question or hypothesis
    • Sufficient background
    • The experimental approach and rationale for the approach are clear
    • The results are clearly presented
    • The interpretation and conclusions are reasonable and logical

Application Process


If you are eligible and wish to be considered for a scholarship, you should complete all of the following by the scholarship deadline for the meeting you wish to attend. It is recommended you begin these steps in advance of the deadline date to ensure completion.

Click here to start a scholarship application.

  See the Scholarship FAQ's

Underrepresented Trainee Scholarships are also available...
Please Click Here for more information about Underrepresented Trainee Scholarship.

  See the Underrepresented Trainee Scholarship FAQ's


If you have any questions, please contact scholarships@keystonesymposia.org.